Cyclacel: Prelim Data in Phase 1/2 Clinical Trial of Oral Fadraciclib in Solid Tumors and Lymphoma

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported today preliminary dose escalation data from its ongoing 065-101 Phase 1/2 clinical study of oral fadraciclib, a cyclin dependent kinase (CDK) 2/9 inhibitor, for the treatment of patients with advanced solid tumors and lymphoma. Of the 18 patients evaluable for response, two out of three T cell lymphoma patients treated achieved partial response and 11 out of 15 patients with various solid tumors achieved stable disease. No dose-limiting toxicities have been observed thus far. Data were presented during a poster presentation at the 34^th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, which is being held on October 26-28, in Barcelona, Spain.

https://www.biospace.com/article/releases/cyclacel-reports-preliminary-data-from-its-phase-1-2-clinical-trial-of-oral-fadraciclib-in-patients-with-solid-tumors-and-lymphoma-at-ena-2022/